Ivacaftor/lumacaftor - Vertex Pharmaceuticals

Drug Profile

Ivacaftor/lumacaftor - Vertex Pharmaceuticals

Alternative Names: Ivacaftor/VX-809; Lumacaftor/ivacaftor; Orkambi; VX-770/VX-809; VX-809/ivacaftor; VX-809/VX-770

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Vertex Pharmaceuticals
  • Developer Vertex Pharmaceuticals
  • Class Amides; Aminophenols; Benzodioxoles; Benzoic acids; Cyclopropanes; Pyridines; Quinolones; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cystic fibrosis

Most Recent Events

  • 10 Nov 2017 The Committee for Medicinal Products for Human Use recommends approval of ivacaftor/lumacaftor for Cystic fibrosis (In children) in European Union
  • 03 Nov 2017 Safety data from a phase III trial in Cystic fibrosis released by Vertex Pharmaceuticals
  • 25 Oct 2017 Vertex plans to file an NDA to US FDA for line extension treatment of patients with Cystic fibrosis (In childrens) in USA in the first quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top